

27 Jul 2018 | News

## QUOTED. July 27, 2018. Opher Shapira.

by

Israeli cancer diagnostics firm Nucleix is planning to scale up European commercial activities to expand the reach of its first product for bladder cancer, *Bladder EpiCheck*. See what Nucleix CEO Opher Shapira said about it [here](#).

"The company is currently in advanced negotiations with additional leading distributors in various European countries to expand its commercial reach. We believe *Bladder EpiCheck* shows the best performance of bladder cancer recurrence detection compared to all other noninvasive solutions. In addition, the test is easy to adopt in any lab and is highly cost-effective." –Opher Shapira, CEO, Nucleix

- Find out more: [Cancer Diagnostics Firm Nucleix Plans European Market Expansion](#)

[Click here](#) for a free trial of *Medtech Insight*